Mirum Pharmaceuticals, Inc. $MIRM Shares Purchased by Penserra Capital Management LLC

Penserra Capital Management LLC increased its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 242.4% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 26,479 shares of the company’s stock after purchasing an additional 18,746 shares during the period. Penserra Capital Management LLC owned approximately 0.05% of Mirum Pharmaceuticals worth $1,941,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in MIRM. Comerica Bank increased its stake in Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after acquiring an additional 278 shares during the last quarter. CWM LLC increased its position in Mirum Pharmaceuticals by 30.8% during the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock worth $50,000 after purchasing an additional 161 shares in the last quarter. Osaic Holdings Inc. increased its position in Mirum Pharmaceuticals by 46.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock worth $56,000 after purchasing an additional 351 shares in the last quarter. Jones Financial Companies Lllp grew its stake in Mirum Pharmaceuticals by 34.0% during the third quarter. Jones Financial Companies Lllp now owns 957 shares of the company’s stock worth $70,000 after buying an additional 243 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Mirum Pharmaceuticals by 14.9% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,914 shares of the company’s stock worth $97,000 after acquiring an additional 248 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research report on Thursday, January 22nd. Wall Street Zen raised Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 17th. TD Cowen reiterated a “buy” rating on shares of Mirum Pharmaceuticals in a report on Monday, January 12th. Leerink Partners set a $100.00 price target on Mirum Pharmaceuticals in a research report on Wednesday, December 10th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and issued a $110.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, December 11th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Mirum Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $107.25.

Insider Activity at Mirum Pharmaceuticals

In related news, Director Patrick J. Heron bought 131,425 shares of the firm’s stock in a transaction on Friday, January 23rd. The shares were purchased at an average price of $68.48 per share, with a total value of $8,999,984.00. Following the completion of the purchase, the director owned 459,010 shares in the company, valued at $31,433,004.80. This represents a 40.12% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Christopher Peetz sold 9,108 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $103.30, for a total transaction of $940,856.40. Following the completion of the transaction, the chief executive officer owned 160,294 shares of the company’s stock, valued at approximately $16,558,370.20. This trade represents a 5.38% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 45,136 shares of company stock valued at $4,352,029 in the last 90 days. Corporate insiders own 14.36% of the company’s stock.

Mirum Pharmaceuticals Stock Up 2.3%

Shares of NASDAQ MIRM opened at $100.47 on Friday. The firm’s 50-day moving average is $83.26 and its 200-day moving average is $74.05. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06. Mirum Pharmaceuticals, Inc. has a 1 year low of $36.88 and a 1 year high of $105.74. The firm has a market capitalization of $5.16 billion, a PE ratio of -116.82 and a beta of 0.49.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The company had revenue of $133.01 million during the quarter, compared to analysts’ expectations of $130.11 million. During the same period in the prior year, the business posted ($0.30) EPS. Mirum Pharmaceuticals’s revenue was up 47.1% on a year-over-year basis. Equities analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.